lopinavir/ritonavir / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 77 Diseases   69 Trials   69 Trials   4434 News 


«12...2526272829303132333435...4546»
  • ||||||||||  Trial completion date, Trial initiation date:  THDMS-COVID19: Fight COVID-19 Trial (clinicaltrials.gov) -  Jun 15, 2020   
    P3,  N=320, Not yet recruiting, 
    Artesunate can shorten the treatment time of COVID-19, improve prognosis and eliminate pathogens, with fewer adverse reactions and a good application prospect. Trial completion date: Nov 2020 --> Mar 2021 | Initiation date: Apr 2020 --> Jul 2020
  • ||||||||||  hydroxychloroquine / Generic mfg., favipiravir / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Trial completion:  Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19 (clinicaltrials.gov) -  Jun 15, 2020   
    P=N/A,  N=40, Completed, 
    Trial completion date: Nov 2020 --> Mar 2021 | Initiation date: Apr 2020 --> Jul 2020 Enrolling by invitation --> Completed
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Clinical, Journal:  Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action. (Pubmed Central) -  Jun 11, 2020   
    Therefore, for the better safety of patients with COVID-19, further clinical trials and large randomized controlled studies are needed to validate the effective role, safety profile, and adverse effects of all the potential drugs. Such a measure requires action at the global level.
  • ||||||||||  hydroxychloroquine / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Enrollment open:  Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1" (clinicaltrials.gov) -  Jun 8, 2020   
    P3,  N=1968, Recruiting, 
    This might be because ante-partum triple antiretroviral protection of the health of mothers with HIV during pregnancy might be neuroprotective for the child, and when continued post partum, could enhance the quality of caregiving for the child through better clinical care for the mother. Not yet recruiting --> Recruiting
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Journal, Adverse drug reaction:  Establishment of a rapid identification of adverse drug reaction program in R language implementation based on monitoring data (Pubmed Central) -  Jun 8, 2020   
    Although all paediatric patients in our cohort had mild or moderate type of COVID-19, the large proportion of asymptomatic children indicates the difficulty in identifying paediatric patients who do not have clear epidemiological information, leading to a dangerous situation in community-acquired infections. In this study, a rapid identification method of adverse reactions based on post marketing drug monitoring data was established in R language environment, which is capable of sending rapid warning of adverse reactions of target drugs in public health emergencies, and providing intuitive evidence for risk management and decision-making of clinical drugs.
  • ||||||||||  emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
    FDA event, Journal:  Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets. (Pubmed Central) -  Jun 8, 2020   
    Further, the azathioprine-treated immunosuppressed ferrets showed delayed virus clearance and low SN titers, resulting in a prolonged infection. As several FDA-approved or repurposed drugs are being tested as antiviral candidates at clinics without sufficient information, rapid preclinical animal studies should proceed to identify therapeutic drug candidates with strong antiviral potential and high safety prior to a human efficacy trial.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Clinical, Retrospective data, Journal:  Clinical Features of COVID-19-Related Liver Damage. (Pubmed Central) -  Jun 4, 2020   
    More than one third of patients admitted to the hospital with SARS-CoV-2 infection have abnormal liver function, and this is associated with longer hospital stay. A significantly higher proportion of patients with abnormal liver function had received lopinavir/ritonavir after admission; these drugs should be given with caution.
  • ||||||||||  azithromycin / Generic mfg., lopinavir/ritonavir / Generic mfg.
    New trial:  COVIDIAB-13: Covid-19 and Diabetes in West of Algeria (clinicaltrials.gov) -  Jun 1, 2020   
    P,  N=100, Recruiting, 
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, lopinavir/ritonavir / Generic mfg.
    Review, Journal:  Emerging pharmacotherapies for COVID-19. (Pubmed Central) -  May 30, 2020   
    Similarly, use of anti-inflammatory cytokines like IL-37 and IL-38 is hypothesised to be useful and is under research. The situation is still evolving and hence there is yet no definitive therapy but to conclude the use of repurposed medications can be a boon till a definitive therapy and vaccines are developed.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Clinical, Review, Journal:  Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review. (Pubmed Central) -  May 29, 2020   
    The most frequently administered drug classes were antivirals, antibiotics, and corticosteroids, and of the 115 reported drugs, the most frequently administered was combination lopinavir/ritonavir, which was associated with a time to clinically meaningful response (complete symptom resolution or hospital discharge) of 11.7 (1.09) days...These data serve as the basis for an open-source registry of all reported treatments given to COVID-19 patients at www.CDCN.org/CORONA. Further work is needed to prioritize drugs for investigation in well-controlled clinical trials and treatment protocols.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Journal:  No Benefit for Lopinavir-Ritonavir in Severe COVID-19. (Pubmed Central) -  May 27, 2020   
    Further work is needed to prioritize drugs for investigation in well-controlled clinical trials and treatment protocols. No abstract available
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, lopinavir/ritonavir / Generic mfg.
    Review, Journal:  Emerging pharmacotherapies for COVID-19. (Pubmed Central) -  May 27, 2020   
    Similarly, use of anti-inflammatory cytokines like IL-37 and IL-38 is hypothesised to be useful and is under research. The situation is still evolving and hence there is yet no definitive therapy but to conclude the use of repurposed medications can be a boon till a definitive therapy and vaccines are developed.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, lopinavir/ritonavir / Generic mfg.
    Review, Journal:  Battling COVID-19: using old weapons for a new enemy. (Pubmed Central) -  May 27, 2020   
    Most of the drugs that are being tried for the treatment have not been evaluated in any randomized controlled trials. The purpose of this review was to summarize the in-vitro and in-vivo efficacy of these drugs on Severe Acute Respiratory Syndrome (SARS-CoV-2) and related viruses (SARS and Middle East Respiratory Syndrome) and evaluate their potential for re-purposing them in the management of COVID-19.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Journal:  A Trial of Lopinavir-Ritonavir in Covid-19. (Pubmed Central) -  May 26, 2020   
    The purpose of this review was to summarize the in-vitro and in-vivo efficacy of these drugs on Severe Acute Respiratory Syndrome (SARS-CoV-2) and related viruses (SARS and Middle East Respiratory Syndrome) and evaluate their potential for re-purposing them in the management of COVID-19. No abstract available
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Journal:  A novel coronavirus (SARS-CoV-2) and COVID-19. (Pubmed Central) -  May 26, 2020   
    The overall case fatality rate is estimated to range from 1 to 3 %, however, it is dependent on age and underlying medical comorbidities. Current potential treatment options include hydroxychloroquine, remdesivir, lopinavir/ritonavir and convalescent plasma.